Nezastomig

奈泽苏米单抗

Report date: 2026/03/19 16:46:42

Base Information

Drug NameNezastomig

Drug Alias NameREGN-5678

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanBiologics > T cell engagers

Mechanisms of ActionAnti-PSMAAnti-CD28

TargetsProstate-Specific Membrane AntigenT-cell-specific surface glycoprotein CD28

Therapy Area/IndicationsProstatic Neoplasms, Castration-ResistantProstatic NeoplasmsCarcinoma, Renal Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesRegeneron Pharmaceuticals Inc

China Registration ClassN/A

Develop Information

Active CompaniesThe University Of Texas MD Anderson Cancer Center Regeneron Pharmaceuticals Inc

Inactive CompaniesN/A

Active IndicationsProstatic Neoplasms, Castration-ResistantProstatic NeoplasmsCarcinoma, Renal Cell

Inactive IndicationsN/A

Other Information

ATC CodeN/A